Pharmaceuticals, Biotechnology and Life Sciences
BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) — Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate…
Successful interim analysis triggered early stop for efficacy Topline study results to be shared at the American Epilepsy Society Annual…
Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint inhibitors,…
Herzliya, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) — Regentis Biomaterials Ltd. (NYSE American: RGNT) (“Regentis”, or the “Company”), a regenerative…
NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory…
Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate Alzheimer’s disease by up…
Robust and clinically meaningful benefits across all three key markers of disease – 68% reduction in proteinuria, stabilization of kidney…
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO…
Webcast set for 8:30 a.m. ET on December 3rdSALT LAKE CITY, Dec. 02, 2025 (GLOBE NEWSWIRE) — Clene Inc. (Nasdaq:…
MONTREAL and CHARLOTTE, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) — Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today…